Our results have demonstrated that, in persons with CD4+ T cell count< 200 cells/μL, the risk ratio of CM events among those who received placebo or no intervention was significant higher than those who received antifungal therapy, suggesting that antifungal prophylaxis significantly reduce the risk of CM events in CrAg+ persons with a higher CD4+ T-cell counts. Here, CD4 is linked to cutaneous mastocytosis.